Drug Trial Radar · NCT07208149
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Jan 29, 2026
Primary completion
Sep 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Shenzhen Majory Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.
Conditions
- Triple-Negative Breast Cancer (TNBC)
Interventions
MR001 Bispecific Antibody for InjectionDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Approximately 6 months
- Maximum Tolerated Dose (MTD) of MR001Time frame: Approximately 6 months
- Incidence of Adverse Events (AEs) as Assessed by CTCAE v5.0Time frame: Approximately 2 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Hunan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.